...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers
【24h】

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers

机译:在激酶抑制剂 - 野alk重新排列的肺癌中,De Novo Alk激酶结构域突变是罕见的

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotinib-naive tumors has not been widely reported and it is unclear if de novo ALIC mutations affect the response to crizotinib.
机译:简介:重排淋巴瘤激酶(ALK)重新排列的肺腺癌对多价ALK抑制剂克里齐替尼反应。 抵抗屈曲inib的常见机制之一是获取alk激酶结构域突变。 然而,屈尿脂 - 幼稚肿瘤中的ALK突变的存在尚未得到广泛报道,如果de Novo Alic突变会影响对屈曲尼的反应,则不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号